nach oben

Reactions Weekly

Erschienen in:

01.06.2023 | Case report

Dasatinib/hydroxycarbamide/ponatinib

Lack of efficacy, anaemia and psoriasiform reaction: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is&colon;

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

"The patient was described as "54-year-old woman" in the initial paragraph of case presentation. And in the remaining case presentation, the patient was described as "he"."

Diaz C, et al. Profound molecular response with ponatinib in chronic phase of chronic myeloid leukemia with resistance to imatinib and dasatinib: Case report and review of the literature. [Spanish]. Revista Medica Heridiana 33: 133-138, No. 2, Apr-Jun 2022. Available from: URL: http://doi.org/10.20453/rmh.v33i2.4247 [Spanish; summarised from a translation]

Titel: Dasatinib/hydroxycarbamide/ponatinib
Lack of efficacy, anaemia and psoriasiform reaction: case report
Publikationsdatum: 01.06.2023
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-41825-1

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Dasatinib/hydroxycarbamide/ponatinib

Lack of efficacy, anaemia and psoriasiform reaction: case report

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Vemurafenib

Multiple drugs

Metronidazole/moxifloxacin/rifampicin

Carbamazepine

Amoxicillin/clarithromycin/esomeprazole

Aspirin/bivalirudin/purinoceptor-P2Y12-antagonists